37 citations,
May 2003 in “Journal of Consumer Marketing”
The debate on direct-to-consumer pharmaceutical ads continues, with consumers finding them educational and doctors concerned about their impact on patient relationships and medication understanding.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a ceaseanddesist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
Anageninc stopping the sale of Pyrilutamide due to a ceaseanddesist order from Kintor, with some speculating that it was either a hoax or subpar product.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.